- Status:
- Topic prioritisation
- Technology type:
- Medicine
- Decision:
- Awaiting decision
- ID number:
- 6496
Provisional Schedule
- Committee meeting: 2:
- 07 January 2026
- Expected publication:
- 18 March 2026
Project Team
- Project lead
- Kate Moore
Email enquiries
If you have any queries please email TACommD@nice.org.uk
- External Assessment Group:
- School of Health and Related Research (ScHARR), University of Sheffield
Stakeholders
- Companies sponsors
- Deciphera Pharmaceuticals (ripretinib)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- GIST Cancer UK
- PAWS-GIST Clinic
- Sarcoma UK
- Professional groups
- Association of Cancer Physicians
- British Society of Gastroenterology
- Cancer Research UK
- Royal College of Physicians
- Royal College of Radiologists
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Institute of Cancer Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 12 November 2025 - 03 December 2025 | Draft guidance |
| 15 October 2025 | Committee meeting: 1 |
| 15 October 2025 | Declaration of interests |
| 19 July 2025 | Invitation to participate |
| 17 March 2025 | Invitation to participate |
| 27 January 2025 - 25 February 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
For further information on how we select topics for development, please see our page about topic prioritisation